Advertisement
Person › Details
Clive R. Wood (Boehringer Ingelheim (Group))
Wood, Clive R. (Boehringer 201403– SVP Discovery Research before Bayer HealthCare + Dyax)
Organisation | Boehringer Ingelheim (Group) | |
Former/major organisation | Bayer HealthCare (Group) | |
Group | Bayer (Group) | |
Product | drug discovery | |
Product 2 | biopharmaceutical | |
Record changed: 2023-10-04 |
Advertisement
More documents for Clive R. Wood
- [1] Boehringer Ingelheim. (10/2/23). "Press Release: Boehringer Ingelheim to Start Phase 1 Development of BI 771716 – a Potential New Treatment for Geographic Atrophy, a Leading Cause of Blindness Worldwide". Ingelheim & Basel....
- [2] Boehringer Ingelheim. (10/19/21). "Press Release: Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis". Paris....
- [3] Twist Bioscience Corporation. (9/9/21). "Press Release: Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration". South San Francisco, CA & Ingelheim....
- [4] Boehringer Ingelheim. (1/9/20). "Press Release: Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases". Ingelheim & Singapore....
- [5] Boehringer Ingelheim. (10/29/19). "Press Release: Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing". Ingelheim....
- [6] Boehringer Ingelheim. (9/20/19). "Press Release: Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases". Ingelheim & Newton, MA....
- [7] Boehringer Ingelheim. (9/3/19). "Press Release: Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/Glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes". Ingelheim & Copenhagen....
- [8] PureTech Health plc. (4/17/19). "Press Release: PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates Using Its Lymphatic Targeting Platform". Boston, MA....
- [9] Boehringer Ingelheim. (1/4/19). "Press Release: Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna". Ingelheim & Cambridge, MA....
- [10] Boehringer Ingelheim. (11/15/18). "Press Release: Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies". Cambridge, MA & Ingelheim....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top